Efficacy of tolvaptan on advanced chronic kidney disease with heart failure: a randomized controlled trial.

Clin Exp Nephrol · 2022 · PMC9385808 · PMID 35471469

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The daily weight change (− 0.58 kg/day vs − 0.39 kg/day; p = 0.057) and the percentage of weight change for 7 days (− 6.37% vs − 4.17%; p = 0.052) showed a trend of decrease in the TLV group compared to the FUR group, but the difference was not significant due to higher water intake in the TLV group (1178 ml/day vs 855 ml/day; p = 0.032).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.